Peripheral T-cell Lymphoma

P2, N=120, Not yet recruiting, BeBetter Med Inc

This study identifies IRENA as an independent prognostic biomarker for nodal PTCL patients, revealing its role in the self-organizing activation of RHOA GTPase. Targeting the IRENA/RHOA/MAPK signaling axis by ASO may represent a potential therapeutic strategy for PTCL.

Despite advances such as brentuximab vedotin-based regimens in CD30-positive disease, relapse rates remain high, particularly in relapsed/refractory (R/R) PTCL...Novel targeted agents, epigenetic therapies, bispecific antibodies, and emerging cellular approaches are reshaping the therapeutic landscape and may serve as effective bridges to allo-HCT or as post-transplant maintenance strategies. This review summarizes current evidence regarding the role of allo-HCT in PTCL, discusses patient selection and transplant-related variables, and explores evolving strategies aimed at improving survival while minimizing toxicity.

Cumulatively, these therapies illustrate both the progress and the ongoing challenges of biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic sequencing, and variability in evidence maturity across targeted strategies. While pirtobrutinib and brentuximab vedotin are supported by increasingly robust clinical evidence in selected lymphoma subtypes, the role of belinostat remains constrained by modest response rates and limited randomized data, underscoring the continued need for biomarker refinement and more precisely individualized therapeutic approaches in NHL precision medicine.

The patient was treated with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone, following which the febrile episodes improved. This case illustrates an uncommon gastrointestinal-predominant presentation of ALK-negative systemic ALCL presenting as fever of unknown origin. This case underscores the importance of continued diagnostic reassessment and symptom-guided tissue acquisition when conventional staging studies are not initially diagnostic, particularly in patients with a history of indolent lymphoma.

P=N/A, N=1000, Not yet recruiting, Ruijin Hospital

P1/2, N=78, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | N=38 --> 78

These findings expand the genotypic spectrum of NBS and demonstrate that compound heterozygosity for non-classical NBN variants can lead to an adult identification of the disease. These cases highlight the importance of integrating genetic and functional analyses to facilitate the recognition of DNA repair disorders beyond childhood and to guide appropriate clinical surveillance and management.

P2, N=30, Completed, Northwestern University | Active, not recruiting --> Completed

Despite CHOP, CHOEP, DA-EPOCH, and AC-CHOP (azacitidine plus chidamide) regimens, the patient experienced primary refractory disease and died 6 months from diagnosis following COVID-19 superinfection. To our knowledge, this is the first case reporting single-cell transcriptomic comparison of skin versus blood compartments in PTCL-NOS, revealing how cutaneous microenvironment sculpts aggressive malignant phenotypes and providing potential targets for compartment-specific therapy.

These findings show improved outcomes in early stage nodal T-cell lymphomas compared to historical data for allcomers. In addition, favorable outcomes in stage I disease treated with chemoradiation support such strategy as an excellent treatment option in this setting.

P3, N=180, Not yet recruiting, Tarapeutics Science Inc.